Product News from the 11/07/06 News Brief

Share this article:
The FDA has approved the first generic version of Galderma’s MetroGel-Vaginal (metronidazole), a treatment for bacterial vaginosis. The generic version, Metronidazole Vaginal Gel, is manufactured by QLT of Fort Collins, CO. The company is eligible for 180 days of generic drug exclusivity. NovaDel Pharma said its NitroMist (nitroglycerin lingual aerosol) has been approved by the FDA for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. North American commercial rights for NitroMist have been licensed to Par Pharmaceutical.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.